In the BALANCE trial, hypersensitivity reactions including anaphylaxis were reported in two pegunigalsidase-treated patients who experienced anaphylaxis during the initial infusion and were positive for anti-pegunigalsidase alfa-IgE antibodies (Wallace et al., 2023). This evidence concerns the gene IGHE and anaphylaxis.